Published in J Control Release on June 15, 2012
Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano (2014) 0.92
Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. Biomaterials (2013) 0.91
Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier. Pharm Res (2014) 0.87
Synthesis and biological evaluation of novel folic acid receptor-targeted, β-cyclodextrin-based drug complexes for cancer treatment. PLoS One (2013) 0.85
In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors. Biomaterials (2013) 0.83
Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int J Nanomedicine (2015) 0.82
Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting. ACS Nano (2013) 0.82
Models and methods to evaluate transport of drug delivery systems across cellular barriers. J Vis Exp (2013) 0.81
Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes. J Control Release (2014) 0.81
Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems. Int J Mol Sci (2015) 0.81
Chitosan-Alginate Microcapsules Provide Gastric Protection and Intestinal Release of ICAM-1-Targeting Nanocarriers, Enabling GI Targeting In Vivo. Adv Funct Mater (2016) 0.80
A DNA-Device that Mediates Selective Endosomal Escape and Intracellular Delivery of Drugs and Biologicals. Adv Funct Mater (2014) 0.79
Endocytosis in gene therapy with non-viral vectors. Wien Med Wochenschr (2016) 0.79
Clathrin-mediated endocytosis is impaired in type A-B Niemann-Pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement. Mol Pharm (2014) 0.79
Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme Delivery. Mol Pharm (2015) 0.78
A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders. Mol Pharm (2016) 0.78
Design strategies and applications of circulating cell-mediated drug delivery systems. ACS Biomater Sci Eng (2015) 0.78
Journey to the Center of the Cell: Current Nanocarrier Design Strategies Targeting Biopharmaceuticals to the Cytoplasm and Nucleus. Curr Pharm Des (2016) 0.78
Magnetic nanoparticles and nanocomposites for remote controlled therapies. J Control Release (2015) 0.78
Targeted endothelial nanomedicine for common acute pathological conditions. J Control Release (2015) 0.77
Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers. Pharm Res (2014) 0.77
Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer. Ther Deliv (2015) 0.76
Distinct subcellular trafficking resulting from monomeric vs multimeric targeting to endothelial ICAM-1: implications for drug delivery. Mol Pharm (2014) 0.76
Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates. Pharmaceutics (2016) 0.75
Assessing the transport of receptor-mediated drug-delivery devices across cellular monolayers. J Biomater Sci Polym Ed (2013) 0.75
The Future of Nanoparticle-Directed Venous Therapy. Semin Intervent Radiol (2017) 0.75
TNYL peptide functional chitosan-g-stearate conjugate micelles for tumor specific targeting. Int J Nanomedicine (2014) 0.75
Plasmon-Enhanced Photocleaving Dynamics in Colloidal MicroRNA-Functionalized Silver Nanoparticles Monitored with Second Harmonic Generation. Langmuir (2016) 0.75
Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders. Int J Mol Sci (2016) 0.75
Grafting Charged Species to Membrane-Embedded Scaffolds Dramatically Increases the Rate of Bilayer Flipping. ACS Cent Sci (2017) 0.75
Fungal lectin MpL enables entry of protein drugs into cancer cells and their subcellular targeting. Oncotarget (2017) 0.75
Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance. Biomaterials (2017) 0.75
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Regulated portals of entry into the cell. Nature (2003) 15.33
Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol (1986) 10.92
Cellular uptake of the tat protein from human immunodeficiency virus. Cell (1988) 10.19
The dawning era of polymer therapeutics. Nat Rev Drug Discov (2003) 7.86
A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol (1986) 7.71
Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev (2003) 7.08
Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol (2007) 6.85
Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A (2006) 6.62
Drug delivery and targeting. Nature (1998) 6.16
Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell (1997) 4.51
Multifunctional nanocarriers. Adv Drug Deliv Rev (2006) 4.46
Nanomedicine: current status and future prospects. FASEB J (2005) 4.28
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res (2003) 3.89
Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer (2002) 3.75
A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J Cell Biol (2004) 3.66
A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions. J Exp Med (1989) 3.58
Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell (2004) 3.55
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. Mol Cell (2001) 3.25
Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res (2000) 3.24
Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov (2006) 3.08
Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains. Nat Cell Biol (2006) 3.08
Endosomal escape pathways for delivery of biologicals. J Control Release (2010) 2.90
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther (2008) 2.69
Targeted drug delivery to tumors: myths, reality and possibility. J Control Release (2011) 2.69
Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev (2007) 2.38
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci (2003) 2.34
Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol (1999) 2.34
18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging (2009) 2.17
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res (2000) 2.07
The origins and evolution of "controlled" drug delivery systems. J Control Release (2008) 2.05
Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov (2010) 2.04
Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci U S A (2002) 2.00
Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J (2009) 1.99
Generation of protein isoform diversity by alternative splicing: mechanistic and biological implications. Annu Rev Cell Biol (1987) 1.97
Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol (2009) 1.97
Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem (1997) 1.96
In vivo biodistribution of nanoparticles. Nanomedicine (Lond) (2011) 1.96
Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther (2006) 1.93
Iron absorption and transport-an update. Am J Hematol (2000) 1.93
Polycation gene delivery systems: escape from endosomes to cytosol. J Pharm Pharmacol (2003) 1.92
Drug targeting. Eur J Pharm Sci (2000) 1.91
Size of IgG-opsonized particles determines macrophage response during internalization. Exp Cell Res (1998) 1.91
Drug targeting to the brain. Pharm Res (2007) 1.79
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res (2009) 1.78
Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med (1996) 1.75
Folate-targeted therapies for cancer. J Med Chem (2010) 1.73
Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet (2002) 1.72
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol (2008) 1.70
Nonviral gene therapy: promises and challenges. Gene Ther (2000) 1.65
Post-translational modifications and their biological functions: proteomic analysis and systematic approaches. J Biochem Mol Biol (2004) 1.64
IGF-1 receptor inhibitors in clinical trials--early lessons. J Mammary Gland Biol Neoplasia (2008) 1.62
Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Expert Opin Drug Deliv (2005) 1.61
Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev (2004) 1.59
ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood (2004) 1.58
GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv Drug Deliv Rev (2004) 1.57
Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Curr Pharm Des (2005) 1.53
Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res (1987) 1.51
Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res (2011) 1.50
Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol (2010) 1.44
Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J (2000) 1.43
An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol (2000) 1.41
Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci U S A (2005) 1.41
Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci U S A (2004) 1.33
High avidity scFv multimers; diabodies and triabodies. J Immunol Methods (1999) 1.32
Cetuximab. Nat Rev Drug Discov (2004) 1.31
Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng (2008) 1.30
Plasmalemmal vesicles represent the large pore system of continuous microvascular endothelium. Am J Physiol (1993) 1.29
Peptide phage display as a tool for drug discovery: targeting membrane receptors. Molecules (2011) 1.28
Acidification and ion permeabilities of highly purified rat liver endosomes. J Biol Chem (1989) 1.28
ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood (2003) 1.28
Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo. Adv Drug Deliv Rev (2001) 1.28
Structure and function of endothelial caveolae. Microsc Res Tech (2002) 1.27
Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. J Control Release (2010) 1.27
Localization of multiple functional domains on human PECAM-1 (CD31) by monoclonal antibody epitope mapping. Cell Adhes Commun (1995) 1.27
Transport across the endothelium: regulation of endothelial permeability. Handb Exp Pharmacol (2006) 1.26
Endothelial endocytic pathways: gates for vascular drug delivery. Curr Vasc Pharmacol (2004) 1.25
Cell adhesion molecules for targeted drug delivery. J Pharm Sci (2006) 1.21
Matrix metalloproteases: underutilized targets for drug delivery. J Drug Target (2007) 1.21
Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol (2001) 1.20
Targeted delivery systems for oligonucleotide therapeutics. AAPS J (2009) 1.19
Exploitation of major histocompatibility complex class I molecules and caveolae by simian virus 40. Immunol Rev (1999) 1.19
Targeted drugs and nanomedicine: present and future. Curr Pharm Des (2009) 1.17
The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation. Biomaterials (2011) 1.17
Protein toxins: intracellular trafficking for targeted therapy. Gene Ther (2005) 1.17
Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm (2009) 1.16
Evaluation of multivalent, functional polymeric nanoparticles for imaging applications. ACS Nano (2011) 1.13
Endothelial transport of macromolecules: transcytosis and endocytosis. A look from cell biology. Cell Biol Rev (1991) 1.11
Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 1.10
Molecular and cellular mechanisms of ectodomain shedding. Anat Rec (Hoboken) (2010) 1.08
Combinatorial ligand-directed lung targeting. Proc Am Thorac Soc (2009) 1.07
Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J Control Release (2008) 1.06
Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv (2008) 1.06
Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano (2011) 1.03
Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev (2004) 1.02
Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Int J Pharm (2006) 1.02
Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs (2000) 1.01
New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.01